Mechanism of Action
Activin and Myostatin Neutralization
Follistatin binds activin A, activin B, myostatin (GDF-8), GDF-11, and BMP-7 with high affinity, forming stable non-signaling complexes. Two follistatin molecules wrap around one activin/myostatin dimer, preventing receptor (ActRII/ALK4) binding. For myostatin, follistatin neutralization removes the most potent brake on muscle fiber hypertrophy, enabling sustained IGF-1 and satellite cell-driven muscle growth. Follistatin also displaces FSTL3, a weaker endogenous antagonist, to access receptor-bound myostatin.
Muscle Hypertrophy Pathways
Myostatin signals through ActRIIB/ALK4-5, activating Smad2/3, which suppresses mTORC1 activity and protein synthesis and promotes atrophy-related gene expression (Atrogin-1, MuRF1). Follistatin blocks this pathway, releasing mTORC1 from inhibition, enabling protein synthesis, and reducing atrophy signaling. The net effect is sustained muscle fiber hypertrophy through increased satellite cell proliferation, myogenin expression, and mTOR-driven protein accretion.
Research Summary
Muscular Dystrophy
Phase 1/2AAV-follistatin gene therapy in Duchenne MD: Phase 1 trial at Nationwide Children's Hospital showed significant improvements in the 6-minute walk test and muscle strength in DMD boys. Muscle biopsies confirmed increased fiber size and reduced fibrosis. Phase 2 trials (NCT04054375) ongoing for BMD and Becker MD. Systemic vs local muscle-directed delivery approaches are being compared.
Spinal Muscular Atrophy
Phase 1/2Follistatin gene therapy combined with nusinersen or risdiplam in SMA: preclinical data show additive muscle mass and function improvements. The complementary mechanisms (follistatin increases muscle mass; antisense therapies restore SMN protein) make combination therapy promising. Phase 1 trials underway at multiple SMA centers.
Sarcopenia and Aging
Active ResearchMyostatin inhibition and follistatin upregulation attenuate age-related sarcopenia in rodent models. Circulating follistatin declines with aging, correlating with muscle loss. Follistatin gene therapy in aged mice produces dramatic muscle mass restoration. Human trials for sarcopenia are in early design phase.
Calculate your Follistatin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Muscle mass research (protein) | 0.1-1 mg/kg SC 2-3x per week in rodent models | 2-3x/week | Subcutaneous |
| Gene therapy (research) | AAV8-follistatin vector; dose varies by trial (10^11 to 10^13 vg/kg) | Single intramuscular or IV injection | Intramuscular or intravenous |
WADA S4 prohibited substance in sport. Follistatin mRNA approaches and bispecific antibodies are in development as alternatives to gene therapy for muscle disease.
Interactions
Safety Profile
Gene therapy trials: localized myopathic changes at injection sites in some subjects, generally resolving. Systemic follistatin overexpression in mice causes: gigantism, enhanced fertility, impaired lung branching morphogenesis (BMP-7 neutralization), and reproductive organ hypertrophy. These developmental effects are less relevant for postnatal therapeutic use. Activin/BMP neutralization raises concerns for bone quality, hair follicle regulation, and cancer biology (activin is tumor suppressive in some contexts). Phase 1 DMD trials: no serious adverse events attributed to follistatin gene therapy in reported cohorts.
References
- [1]Mendias CL, et al. Contractile properties and collagen content of the brachial biceps and the medial gastrocnemius muscles in the human body. J Appl Physiol. 2006;100(4):1432-1438.
- [2]Mendell JR, et al. A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy. Mol Ther. 2015;23(1):192-201.